4523 Share Price Performance
JP¥0
-5058.00 (-100.00%)
Price JP¥0
Fair ValueJP¥3,600.00
Share Pricen/a
Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09
Eisai Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
4523 Community Narratives
AN
Fair Value JP¥3.6k 25.1% overvalued intrinsic discount
Japan HTA Review And MFN Proposals Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value JP¥6k 25.0% undervalued intrinsic discount
Aging Demographics And Early Diagnosis Will Drive Neurology Advancement
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value JP¥5.03k 10.4% undervalued intrinsic discount
Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
Key Takeaways Rapid adoption of innovative Alzheimer's diagnostics and therapies, plus operational efficiencies, are expanding Eisai's eligible patient pool, driving revenue growth, and boosting profitability. Strong global rollout and premium market positioning for LEQEMBI support sustained demand, further diversification, and long-term earnings stability as the aging population increases.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
JP¥5.03k
10.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
3.95% p.a.
Profit Margin
7.53%
Future PE
23.91x
Share price in 2028
JP¥5.78k
Japan HTA Review And MFN Proposals Will Squeeze Margins
Key Takeaways Intensifying price pressures, patent losses, and heavy dependence on a narrow pipeline threaten revenue stability and make future earnings highly susceptible to disruption. Regulatory hurdles, market stagnation, and demographic trends pose serious long-term risks to growth, profitability, and competitive positioning.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
JP¥3.6k
25.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
0.93% p.a.
Profit Margin
5.41%
Future PE
25.99x
Share price in 2028
JP¥4.13k
Aging Demographics And Early Diagnosis Will Drive Neurology Advancement
Key Takeaways Rapid adoption of LEQEMBI and ease of at-home dosing may make it the default treatment, significantly boosting revenue and market share. Streamlined operations and early-stage pipeline advances position Eisai for long-term profit growth and broader market leadership in neurology.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
JP¥6k
25.0% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
8.83% p.a.
Profit Margin
9.22%
Future PE
20.28x
Share price in 2028
JP¥6.88k
Snowflake Analysis
Eisai Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 09, 2026
- 175.13
- 78.29%
- 6.14%
- 26.9%
About 4523
- Founded
- 1941
- Employees
- 10917
- CEO
- WebsiteView website
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer’s disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for primary generalized tonic-clonic seizures; and Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. It operates in Japan, China, the Americas, Europe, the Middle East, Africa, and East Asia Global South. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
